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Summary 
Some of the metabolites of arachidonic acid formed in the 
lipoxygenase and cyclooxygenase pathways stimulate insulin 
release. We studied the relative importance of each of these 
pathways in the modulation of glucose-induced insulin release by 
using inhibitors of arachidonate metabolism. Perfusion of the 
isolated rat pancreas with two chemically different inhibitors of 
cyclooxygenase, flurbiprofen and sodium salicylate, markedly 
inhibited prostaglandin E 2 release, but had l i t t l e  effect on 
glucose-induced insulin release or on potentiation of insulin 
release caused by prior exposure to glucose. On the other hand, 
nordihydroguaiaretic acid (NDGA), a lipoxygenase inhibitor, not only 
inhibited both phases of glucose-induced insulin release but also 
abolished the potentiation effect. These effects of NDGA prevailed, 
when i t  was administered together with flurbiprofen, which caused 
profound inhibition of prostaglandin E? release. We conclude that 
I) lipoxygenase pathways play a dominaSt role in glucose-stimulated 
insulin release, and 2) endogenous lipoxygenase metabolites 
influence the potentiating effect of glucose on the release of 
insulin in response to a subsequent stimulation. 
We have shown that the administration of exogenous prostaglandins (PGs) 
induces insul in release from the isolated perfused rat pancreas when the 
glucose concentration in the perfusion medium is physiological ( I -3 ) .  Using 
perifused i s le ts ,  also Burr and Sharp observed a st imulat ion of insul in release 
by PGE at a low glucose concentration (4). Other invest igators fa i led  to 
observe an ef fec t  of PGs under these condit ions (5,6).  Conf l icts also arose 
when glucose-stimulated insul in secretion was studied; some authors reported 
enhancement (5,6),  while others suppression of insul in release (4,7-9).  
Experiments with cyclooxygenase inh ib i to rs  also yielded disparate resul ts ,  
suggesting i nh ib i t i on ,  st imulat ion or lack of an e f fec t  by endogenous PGs on 
insul in release (7,10-13). Is le ts  incorporate radiolabeled arachidonate into 
various phospholipids (14,15). Phospholipases l iberate arachidonate from the 
phospholipids; these enzymes are activated by calcium and glucose (16). In 
i s le t s ,  arachidonate is then converted by cyclooxygenases to PGs (14,15). 
Intact or sonicated rat pancreatic i s le ts ,  and neonatal rat pancreatic cel ls  in 
cul ture release a var ie ty  of PGs (8,14,17,18). Recently, at tent ion has shi f ted 
to products of the lipoxygenase pathway of arachidonate metabolism as possible 
mediators of insul in secretion (19-21); the is le ts  have been shown to produce 
these metabolites as well (16,20,22). 
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Our aim in this investigation was to study the role of endogenously 
generated metabolites of arachidonate in glucose-stimulated insulin secretion 
by the isolated perfused pancreas. We studied the effects of a lipoxygenase 
inhibitor, nordihydroguaiaretic acid, two cyclooxygenase inhibitors, 
flurbiprofen and sodium salicylate, and the combination of flurbiprofen and 
nordihydroguaiaretic acid on the dynamics of glucose-induced insulin and PG 
release. We also explored the influence of these compounds on the "priming" 
effect of antecedent administration of glucose on subsequent glucose-induced 
insulin release (23,24). We found that the inhibition of lipoxygenases not 
only diminished glucose-induced insulin release, but also nearly abolished the 
priming or potentiating effect of a previous glucose stimulus. 
Mater ia ls  and Methods 
Young, male Sprague-Dawley rats weighing 250-300 grams (Charles River 
Laboratories, Wilmington, MA) were fasted overnight. The pancreas of an animal 
was surgically removed, affixed to a fiberglass platform in anatomically 
correct position, and transferred to a multiple-channel perfusion apparatus 
(2). Perfusion buffer entered the aortic cannula at a rate of 2.5 ml/min and 
was collected from a portal vein cannula. Exocrine secretion was drained via a 
duodenal tube. The perfusion buffer solution, which was continually gassed 
with 95% oxygen and ,5% carbon dioxide to maintain pH at 7.4 was composed of 
118.5 mM sodium chloride, 3.5 mM potassium chloride, 1.0 mM magnesium sulfate, 
1.2 mM monobasic potassium phosphate, 2.5 mM calcium chloride, 24.9 mM sodium 
bicarbonate, 40 g / l i t e r  dextran and 2 g / l i t e r  bovine serum albumin. The basal 
perfusion solution also contained 5.6 mM D-glucose. 
The pancreas was equilibrated with the basal perfusion solution for 30 
min. Fifteen minutes after the start of the experiment, the channel was 
switched to one that contained a perfusion solution with 16.7mM glucose. This 
stimulatory period lasted 15 min (Period I, 15-30 min) and was followed by a 
30-min perfusion with the basal solution and a second 15-min period of 
perfusion with 16.7mM glucose (Period 2, 60-75 min). In the experiments where 
the inhibitor drugs were employed, the perfusion of nordihydroguaiaretic acid 
(NDGA, lOpM, Sigma), flurbiprofen (FLR, lpM, Upjohn), or sodium salicylate 
(SAL, 1.2mM, Sigma) was begun at minute 5 and lasted throughout the rest of the 
experimental period. Effluent, collected every minute with the aid of a 
fraction collector, was quickly chil led, then frozen. Selected samples were 
radioimmunoassayed for insulin (25), and PGE 2 (26). 
The release of i nsu l i n  and PGE? was quant i f ied  as areas under the curve 
(2) .  Incremental areas were obtained by subtract ing basel ine re lease;  
secret ion rates corresponding to respect ive response areas were derived by 
mu l t i p l y i ng  the incremental areas by 2.5. The presented values are means 
+ standard e r ro rs .  S t a t i s t i c s  were calculated using a two- ta i led  Student's 
t - t e s t  and analys is of variance (27). 
Results 
Control Experiments 
In the contro l  experiments conducted in the absence of any drugs, i nsu l i n  
release occurred in a biphasic pattern during both periods of perfusion with 
16.7mM glucose (Fig 1). Cumulative secret ion of i nsu l i n  during Period 2 of 
exposure to high concentrat ion of glucose was greater ( p < O . O l )  than that  
observed during Period 1 ( Table I ) .  
PGE 2 was released in a s lowly cumulative and steady manner; an e f f ec t  of 
changes in glucose concentrat ion was not d i sce rn ib le  (Fig 2).  The incremental 
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amount of PGE 2 released during the period 5-90 min was 447+36 nmol. In a 
separate set of experiments, PGE 9 release during continuous perfusion with 
5.6mM glucose was simi lar in magnitude and pattern (data not shown). 
Ef fect  of nordihydroguaiaretic acid 
Start ing at time 5 min, lOpM NDGA was perfused in order to inh ib i t  
pancreatic lipoxygenases. As compared to the control experiments, with NDGA, 
the late phase of glucose-induced insul in release was inhib i ted in Period 1, 
and early as well as the late phases of release were inh ib i ted in Period 2 (Fig 
1, Table I ) .  The inh ib i to ry  e f fec t  of NDGA on glucose-induced insul in release 
was greater in Period 2 than in Period I ,  so that the magnitudes of hormone 
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FIG. 1 
Effect of nordihydroguaiaret ic acid {NDGA) in the presence or absence 
of f lu rb ipro fen (FLR) on glucose-induced insul in release during two 
15-min periods. Numbers of experiments appear in parentheses. 
At the concentration employed, NDGA also inh ib i ted the release of PGE? to 
44% of the amount released during the control experiments (Fig 2). The amount 
released from 5 to 90 min was 198+52 nmol (p<O.O05 vs cont ro l ) .  
Effects of f lu rb ip ro fen  and sodium sa l icy la te  
Since, with NDGA, the cyclooxygenase enzyme also appeared to have been 
inh ib i ted ,  the ef fects  of two chemically unrelated cyclooxygenase inh ib i to rs  
were explored. In two separate series of experiments, from time 5 min onwards, 
the perfusion solut ion contained e i ther  IpM FLR or 1.2mM SAL. Total PGE 2 
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release decreased to 13% of control with FLR, and to less than I% with SAL 
(58~56 and -15~28 nmol, respectively, p<0.005 vs control; Fig 2). 
During Periods I and 2, both phases of glucose-induced release increased 
modestly, both with FLR and SAL (Table I ) .  With FLR, insul in  release was 124% 
of control during Period I ,  and 130% during Period 2; with SAL the 
corresponding values were 133% and 148%. None of these increases were 
s ign i f i can t .  With ei ther drug, glucose-induced insul in release during Period 2 
was greater (p,CO.01) than that during Period I ,  with a ra t io  s imi lar  to that 
seen in control experiments. 
TABLE I 
Incremental Amounts of Immunoreactive Insul in Released 
by the Isolated Rat Pancreas 
N 
Control 6 
NDGA IOuM 6 
FLR ipM 6 
SAL 1.2mM 6 
NDGA lOpM 5 
+ FLR IpM 
Insulin Release 
Period I a Period 2 a 
Acute Delayed Total Acute Delayed Total Ratio 
(15-20min) (20-35min) (15-35min) (60-65min) !54-80min) (60-80min) P2/PI 
2.7+0.a 16.8+2.4 19.5+2.7 9.4+1.4 36.~+4,2 46.3+2.2 ?.4 
1.9+0,6 7.4+1.8 c 9,2+2,3 b 3.1+0.8 d I0,4+2.5 d 13.4+3.3 d 1,5 
4,1+0,9 20.1+3.7 24.1+~,5 !3.5+2.0 46.8+4.5 60.3+6.4 2.5 
4.2+1.3 21.7+6.2 25.9+7.5 17.4+4.7 51.2+12.1 68.6+16.7 2.6 
2.1+0,8 5,9+I.6 d 8.0+2.3 c 2.7+0.5 d IO.O+P.7 d 12.6+3.2 d 1.6 
Footnotes: 
NDGA = nordihydroguaiaretic acid, FLR = f lu rb ip ro fen ,  SAL = sodium 
sa l i cy la te ,  administered from 5-min time point onwards. Glucose 
concentration was increased from 5.6mM to 16.7mM twice, from 15 to 30 
min, and from 60 to 75 min. 
a Values represent the means + SE in nanomoles for the time periods 
indicated. 
b p <0.05;  c p~O.Ol ,  d D<O.O05 vs control. 
Effect of nord!hydroguaiaretic acid plus flurbiprofen 
Because the select ive inh ib i t ion  of cyclooxygenase modestly promoted 
glucose-induced insul in  release, in a f i na l  series of experiments lOpM NDGA was 
administered together with IpM f lurb iprofen to find out whether NDGA could 
exert i t s  inh ib i to ry  ef fects at a time cyclooxygenase was profoundly 
inh ib i ted .  In these experiments, to ta l  PGE 2 release was inhib i ted to 9% of the 
corresponding levels observed during control experiments (Fig 2, 41+51_ nmol, 
p < 0.005). This degree of inh ib i t ion  was substant ia l ly  less than the 
inh ib i t i on  seen with NDGA alone (44% of cont ro l ) .  
Combined administration of NDGA and FLR affected glucose-induced insulin 
release in a manner very similar to that seen with NDGA alone. During Period 
I, the late phase, and during Period 2 both phases of insulin release were 
inhibited, and the difference in the magnitudes of the release during Periods I 
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FIG. 2 
Effect of nordihydroguaiaretic acid (NDGA), f lurb iprofen (FLR), sodium 
sa l i cy la te  (SAL) and NDGA + FLR on PGE 2 release from the isolated rat 
pancreas. Numbers of experiments appear in parentheses. 
Discussion 
The resul ts of our study indicate that the lipoxygenase pathway of 
arachidonic acid metabolism plays a far  greater role than the cyclooxygenase 
pathway in the release of insul in in response to glucose. 
In this study we were able to monitor the a c t i v i t y  of the cyclooxygenase 
but not the lipoxygenase pathway. We assume that with NDGA pancreatic 
biosynthesis of autacoids in the lipoxygenase pathways of arachidonate 
metabolism was inh ib i ted.  This ef fect  of NDGA was documented conclusively in 
other systems (28). The assumption that inh ib i t i on  of pancreatic lipoxygenases 
is the basis for the inh ib i to ry  action of NDGA on glucose-induced insul in 
release is plausible also for the fol lowing reasons: i )  lipoxygenase a c t i v i t y  
has been documented in pancreatic i s le ts  (16,22); 2) we have demonstrated that 
the administration of leukotriene B a (LTBa), LTC a, LTD a and LTEm, a l l  
metabolites of arachidonate activated- by 5Jlipoxyge'nase, s t imulate insu l in  
release (29); and 3) Metz et al have shown that 12-hydroperoxyeicosatetraenoic 
acid, a 12-1ipoxygenase-activated metabolite of arachidonate, stimulates 
insul in  release (20). 
At concentrations higher than those we have employed, NDGA has been shown 
to i nh ib i t  not only lipoxygenases, but also the cyclooxygenase (30). In the 
present study, the observed decreases in PGE 2 release indicate that ,  
1704 Lipoxygenase Action on Insulin Release Vol. 34, No. 18, 1984 
unexpectedly, IO~M NDGA moderately inhib i ted the cyclooxygenase. We are 
confident that the inh ib i t i on  of cyclooxygenase did not play any role in the 
inh ib i t i on  of glucose-induced insul in release by NDGA, because i)  profound 
inh ib i t i on  of PGE9 release by two chemically unrelated inh ib i to rs  of 
cyclooxygenase (31,32) did not af fect  insul in release, and 2) the magnitude of 
i nh ib i t i on  of glucose-induced insul in release by NDGA was the same in the 
presence or absence of FLR. 
Unlike our observation in the present experiments, we demonstrated 
previously that increases in the concentration of glucose in the range of 4- 
20mM induced dose-related increases in PG release from isolated rat i s le ts  
incubated for  20 hours (33). We interpreted those f indings as an indicat ion of 
act ivat ion of phospholipase A~ by glucose. Our f a i l u re  to see an augmentation 
of PGE 2 release in conjunct3on with the increases in the concentration of 
glucose in the present study may be due to the r e l a t i v e l y  short duration of the 
experiments or to potent ia l  d i f ferences between glucose sens i t i v i t y  of 
phospholipases in the exocrine and the endocrine ce l ls  of the pancreas. 
In our control experiments, we observed the fami l ia r  phenomenon of 
potent ia t ion of glucose-induced insul in release by antecedent administrat ion of 
glucose. Inh ib i t ion  of lipoxygenase with NDGA abolished th is  priming e f fec t .  
The abol i t ion of the priming ef fec t  could be due to a longer duration of 
exposure to NDGA in Period 2 than in Period i of glucose-induced insul in  
release. Nevertheless, our observation suggests that l ipoxygenase-activated 
products of arachidonate metabolism par t ic ipa te  in the priming action of 
glucose on glucose-induced insul in release. Prior studies assign an important 
role to the metabolism of glucose in the priming e f fec t  ( 2 3 , 2 4 ) .  We speculate 
that lipoxygenase products may contr ibute to the priming ef fec t  by enhancing 
the metabolism of glucose. The same mechanism could also explain the 
inh ib i t i on  of glucose-induced insul in release which we observed with NDGA 
independent of the priming e f fec t  (Period i ) .  Val idat ion of th is proposal must 
await studies on the involvement of lipoxygenase products in the metabolism of 
glucose. 
By using the perfused pancreas model, we were able to evaluate the 
inf luence of lipoxygenase products on d i f f e ren t  phases of insul in release. 
Both the ear ly and the late phases of glucose-induced insul in release were 
inh ib i ted in Period 2, but only the late phase was inhib i ted in Period I .  I f  
one were to assume that the inh ib i t i on  of the early phase release in Period 2 
is related to the abol i t ion of the priming e f fec t ,  then a select ive st imulatory 
e f fec t  of endogenous lipoxygenase products on the late phase of insul in release 
may be postulated. 
In the present study we have not observed an ef fec t  of cyclooxygenase 
inh ib i to rs  on glucose-induced insul in release. In a previous study with the 
isolated perfused rat pancreas, under somewhat d i f fe ren t  experimental 
condit ions, we observed that I~M, but not lOnM f lurb ipro fen inhib i ted insul in 
release in response to 30-minute perfusions with 16.7mM glucose (34). A reason 
for th is inconsistency is not readi ly  apparent at th is time. The magnitude of 
the problem of the inconsistency in the ef fects of cyclooxygenase inh ib i to rs  on 
insul in release is revealed by comprehensive review of the work of various 
invest igators (35). Previously we provided ample evidence that certain 
prostaglandins stimulate insul in release (1-3). We believe that when 
arachidonate is abundant, such as when phospholipase A 2 is stimulated by 
glucose (16), variable degrees of inh ib i t i on  of cyclooxygenase causes a 
diversion of proport ionate amounts of arachidonate to the lipoxygenase pathway 
(36,37). The resul tant increase in the biosynthesis of leukotr ienes and 
hydroperoxy-fatty acids could then stimulate insul in release, thus masking the 
reduction in the st imulatory e f fec t  of prostaglandins. This hypothesis needs 
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to be tested fur ther .  Our present results with the cyclooxygenase inhib i tors 
c lear ly  document that the lipoxygenase pathways of arachidonate metabolism 
dominate in influencing insul in release. 
We conclude that endogenous products of the lipoxygenase pathways of 
arachidonate metabolism amplify stimulated insul in release and part ic ipate in 
the potentiat ion of glucose-induced insulin release caused by antecedent 
administration of glucose. 
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